Day-7 Patch-Test Findings in 3,292 Patients
Doctor’s Notes · Life in Motion · Evidence Review
Editorial disclosure: The featured image is an AI-created illustration of a fictional work or daily-life scene. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.
Reader question: What can this study tell workers, families and occupational-health teams—and what would go beyond the evidence? This review keeps every number attached to its population, denominator, comparator and timepoint.
Study snapshot
| Study element | Reported detail |
|---|---|
| Population | 3,292 consecutive patients tested from 2008 through 2018 with at least 43 allergens from TRUE Test panels 1 and 2 plus investigator-loaded allergens. |
| Design | Retrospective comparison of day-3 and day-7 patch-test readings. |
| Comparator | Reactions already positive on day 3 versus reactions first positive on day 7, analyzed by allergen group and patient characteristics. |
| Timepoint | Readings on day 3 and day 7 across a ten-year testing period. |
| Key result | Four hundred forty-seven patients (13.6%) had at least one new positive reaction on day 7. New day-7 reactions were more frequent for topical medications (OR 2.60, 95% CI 1.92-3.51) and corticosteroids (OR 1.87, 1.09-3.21). |
| Funding/conflict context | The PubMed XML record retrieved for this review lists no grant or conflict-of-interest statement. |
What was actually measured?
Four hundred forty-seven patients (13.6%) had at least one new positive reaction on day 7. New day-7 reactions were more frequent for topical medications (OR 2.60, 95% CI 1.92-3.51) and corticosteroids (OR 1.87, 1.09-3.21).
The timing of a diagnostic reading changes what is detected. The extra 13.6% refers to patients with a new day-7 reaction, not proof that every late reaction explained the presenting dermatitis.
The denominator defines the scope. A patch-test clinic, selected case series, compensation registry, online questionnaire, workplace cohort and general-population survey answer different questions. A percentage from one cannot be silently transferred to the others.
What the result does not prove
This was a referred clinical population, later positivity does not automatically establish relevance and the study does not show that every patient or allergen needs identical reading schedules.
Association, timing and biological plausibility can strengthen an occupational interpretation, but observational evidence cannot automatically establish individual causation. Referral patterns, reporting practices, task mix, protective equipment, nonwork exposures and access to care may all change an estimate.
A PubMed record is a bibliographic source. PubMed indexing is not NIH endorsement of the authors' conclusions, this interpretation or any product.
Exposure detail matters more than the job label
Workers with the same title can handle different materials for different durations. Useful documentation identifies the exact product or process, the route of contact, glove or PPE material, wetness, friction, heat, dust, splash potential, frequency and how symptoms change away from the task.
A symptom survey can identify a pattern, a clinical examination can refine the differential diagnosis, and patch testing can identify delayed sensitization. None of those steps alone proves that a workplace material caused an individual condition. Clinical relevance still requires a credible exposure and time course.
Questions worth recording
- Which task, product, glove, tool, metal, resin, cleanser, food, plant, dust or surface came before symptoms?
- Where did the change begin, and did it improve on days away or after a process or PPE change?
- How often were hands wet, washed, disinfected, occluded, rubbed, heated or exposed to cold?
- Were labels, ingredient information and safety-data sheets reviewed with occupational health?
- Did the problem affect dexterity, sleep, pace, attendance, work quality or safety?
Prevention comes before cosmetic care
Substitution, closed systems, local exhaust, splash control, safer cleaning methods, training and correctly selected protective equipment address exposure at its source. Gloves are not automatically protective: material, fit, breakthrough time, sweating, reuse and rubber accelerators all matter.
Do not deliberately place workplace products on skin to test a theory. Persistent, recurrent or spreading symptoms, drainage, fever, breathing symptoms, severe pain, rapidly worsening redness or major loss of function warrant professional evaluation.
Primary research and guidance
- Primary research record: PubMed PMID 31116435
- NIOSH: occupational skin exposure
- NIAMS: atopic dermatitis
- American Academy of Dermatology: eczema skin care
Where Dr. Arsy #003 fits
Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003. Its findings do not show that #003 treats, cures or prevents eczema, relieves pain or itch, neutralizes workplace chemicals, is appropriate for every person, or provides pediatric or 24-hour efficacy.
Continue the evidence series
- Job-Exposure Matrix Findings Across 56,978 Dutch Adults
- Hand and Forearm Symptoms in 726 Metalworkers Versus 84 Office Workers
- Observed Versus Reported Wet Work in 114 Workers Across 15 Occupations
- Pesticide Patch Tests in 30 Agricultural Workers and 20 Controls
Evidence note: This educational article separates reported findings from interpretation. It is not a diagnosis, treatment recommendation or workplace-safety determination.